Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(1)
Other(2)

Detailed Status

unknown2
Withdrawn1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

withdrawn125%
completed125%
unknown250%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

NCT04388475
unknown

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

NCT05518838
unknownphase_1

Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients

NCT01672463
withdrawnphase_1

Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants

NCT03649464

Clinical Trials (4)

Showing 4 of 4 trials
NCT04388475Phase 2

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

Completed
NCT05518838

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

Unknown
NCT01672463Phase 1

Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients

Unknown
NCT03649464Phase 1

Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4